MARKET

CFRX

CFRX

ContraFect
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.010
-0.030
-0.74%
After Hours: 4.010 0 0.00% 16:00 09/24 EDT
OPEN
3.990
PREV CLOSE
4.040
HIGH
4.040
LOW
3.944
VOLUME
42.17K
TURNOVER
--
52 WEEK HIGH
7.63
52 WEEK LOW
3.100
MARKET CAP
157.72M
P/E (TTM)
-9.4866
1D
5D
1M
3M
1Y
5Y
ContraFect Corporation to Present at the 2021 Cantor Global Virtual Healthcare Conference
ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening...
GlobeNewswire · 3d ago
--SVB Leerink Starts ContraFect at Outperform with $14 Price Target
MT Newswires · 09/09 12:01
SVB Leerink Initiates Coverage On ContraFect with Outperform Rating, Announces Price Target of $14
SVB Leerink analyst Roanna Ruiz initiates coverage on ContraFect (NASDAQ:CFRX) with a Outperform rating and announces Price Target of $14.
Benzinga · 09/09 10:50
CFRX: Awaiting Interim Futility Analysis for Phase 3 DISRUPT Trial…
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Phase 3 DISRUPT Trial Continues ContraFect, Inc. (NASDAQ:CFRX) is currently conducting the Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) trial of e...
Zacks Small Cap Research · 08/30 11:18
Telemetry Investments, L.L.C. Buys Angel Pond Holdings Corp, Silver Spike Acquisition Corp II, ...
GuruFocus News · 08/18 18:38
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
White Pine Capital Llc Buys BTC BlackRock Short Maturity Bond ETF, Innovator S&P Investment ...
GuruFocus News · 08/16 15:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CFRX. Analyze the recent business situations of ContraFect through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CFRX stock price target is 13.75 with a high estimate of 23.00 and a low estimate of 6.50.
EPS
Institutional Holdings
Institutions: 88
Institutional Holdings: 28.78M
% Owned: 73.17%
Shares Outstanding: 39.33M
TypeInstitutionsShares
Increased
15
898.30K
New
13
520.93K
Decreased
20
2.60M
Sold Out
26
1.49M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/President/Chief Executive Officer/Director
Roger Pomerantz
Vice Chairman/Director
Steven Gilman
Chief Financial Officer/IR Contact Officer
Michael Messinger
Executive Vice President
Cara Cassino
Senior Vice President
Gary Woodnutt
General Counsel/Secretary
Natalie Bogdanos
Lead Director
Sol Barer
Independent Director
Lishan Aklog
Independent Director
Jane Barlow
Independent Director
David Low
Independent Director
Michael Otto
Independent Director
Cary Sucoff
No Data
About CFRX
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infection. Its lead DLA candidate includes exebacase, which is an investigational novel lysin that targets Staphylococcus aureus (Staph aureus), including methicillin-resistant (MRSA) strains, which causes serious infections such as bacteremia, pneumonia, and osteomyelitis. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. The Company is conducting Phase II clinical study of exebacase for the treatment of Staph aureus bacteremia, including right-sided endocarditis, caused by MRSA or MSSA.

Webull offers kinds of ContraFect Corp stock information, including NASDAQ:CFRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CFRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CFRX stock methods without spending real money on the virtual paper trading platform.